Paradigm Genetics gets funds for liver marker work:
This article was originally published in Clinica
Executive Summary
Paradigm Genetics has received a $742,000 award in the US to find biochemicals in urine, serum and liver tissue that predict the early onset of drug-induced liver injury. Biomarkers discovered by the firm could provide diagnostics that help pharmaceutical companies better assess drug candidate safety and that might also enable physicians to more effectively diagnose and treat disease. Under the award, from the National Institutes of Health, Paradigm will conduct preclinical studies on three compounds known to cause liver damage, using mass spectrometry to measure changes in hundreds of small molecular weight biochemicals that may be linked to liver toxicity.
You may also be interested in...
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.
Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire
Clarke helped launch GDUFA I and negotiate GDUFA II, chaired the CDER Executive Committee and oversaw many other programs in the US FDA’s drugs center.